A high-throughput biophotonics instrument to screen for novel ocular photosensitizing therapeutic agents

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 5, 2010, Pages 2705-2720

  Butler, Mark C ^a   Itotia, Patrick N ^a,b   Sullivan, Jack M ^a,b,c  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; FLUORESCENT DYE; MALACHITE GREEN; PHOTOSENSITIZING AGENT; RED FLUORESCENT PROTEIN; TETRAMETHYLRHODAMINE; TETRAMETHYLROSAMINE; UNCLASSIFIED DRUG; GREEN FLUORESCENT PROTEIN; KILLER RED PROTEIN, ANTHOMEDUSAE;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETERMINATION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LIGHT EMITTING DIODE; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA MACULA DEGENERATION; CELL LINE; DRUG SCREENING; INSTRUMENTATION; METHODOLOGY; OPTICS; PHOTOCHEMOTHERAPY;

CELL LINE; DRUG EVALUATION, PRECLINICAL; GREEN FLUORESCENT PROTEINS; HUMANS; OPTICS AND PHOTONICS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 77952479663     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2862     Document Type: Article

References (43)

1. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998;90:889-905.
2. Kessel D, Luo Y. Photodynamic therapy: a mitochondrial inducer of apoptosis. Cell Death Differ. 1999;6:28-35.
3. Bulina ME, Chudakov DM, Britanova OV, et al. A genetically encoded photosensitizer. Nat Biotechnol. 2006;24:95-99.
4. Miller J, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999; 117:1161-1173.
5. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group: photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. TAP Report 1. Arch Ophthalmol. 1999;117:1329-1345.
6. Bressler N. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group: photodynamic therapy of subfoveal choroidal neovascularization in related age macular degeneration with verteporfin: two year results of 2 randomized clinical trials. TAP Report 2. Arch Ophthalmol. 2001;119:198-207.
7. Kramer M, Miller J, Mihaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Ophthalmology. 1996;103:427-438.
8. Klais CM, Ober MD, Freund KB, et al. Choroidal infarction following photodynamic therapy with verteporfin. Arch Ophthalmol. 2005;123:1149-1153.
9. Brown DM, Kaiser PK, Michels M, et al. Anchor Study Group. Ranibizumab versus verteporin for neovascular age-related macular degeneration. New Engl J Med. 2006;355:1432-1444.
10. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124:1532-1542.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
12. Bashur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2007;125:1357-1361.
13. Gelisken F, Lafaut BA, Inhoffen W, Voelker M, Grisanti S, Bartz-Schmidt KU. Clinicopathological findings of choroidal neovascularization following verteporfin photodynamic therapy. Br J Ophthalmol. 2004;88:207-211.
14. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GOH. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol. 2002;120:835-844.
15. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol. 1991;53:549-553.
16. Lange N, Ballini J-P, Wagnieres G, van den Bergh H. A new drugscreening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest Ophthalmol Vis Sci. 2001;42:38-46.
17. Tran TC, Sneed B, Haider J, et al. Automated, quantitative screening assay for antiangiogenic compounds using transgenic zebrafish. Cancer Res. 2007;67:11386-11392.
18. Jones PA, King AV. High throughput screening (HTS) for phototoxicity hazard using the in vitro 3T3 neutral red uptake assay. Toxicol In Vitro. 2003;17:703-708.
19. Dixit M, West M, Earl L, Lovell W. An in vitro cell culture method for screening of photoirritation using 3T3 neutral red uptake assay. Toxicol In Vitro. 1993;8:759-761.
20. Nathalie D, Yannick G, Caroline B, et al. Assessment of the phototoxic hazard of some essential oils using modified 3T3 neutral red uptake assay. Toxicol In Vitro. 2006;20:480-489.
21. Sullivan JM. Low-cost monochromatic microsecond flash microbeam apparatus for single-cell photolysis of rhodopsin or other photolabile pigments. Rev Sci Inst. 1998;69:527-539.
22. Zorov DB, Filburn CR, Klotz L-O, Zweier JL, Sollott SJ. Reactive oxygen (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. J Exp Med. 2000;192:1001-1014.
23. Detty MR, Prasad PN, Donnelly DJ, Ohulchanskyy T, Gibson SL, Hill R. Synthesis, properties, and photodynamic properties in vitro of heavy-chalcogen analogues of tetramethylrosamine: Bioorg Med Chem. 2004;12:2537-2544.
24. Oseroff AR, Ara G, Wadwa KS, Dahl T. Selective photochemotherapy with cationic photosensitizers, In: Kessel D, ed. Photodynamic Therapy of Neoplastic Disease. Vol I. Boca Raton, FL: CRC Press; 1990:296-297.
25. Stillman BW, Gluzman Y. Replication and supercoiling of Simian Virus 40 DNA in cell extracts from human cells. Mol Cell Biol. 1985;5:2051-2060.
26. Sullivan JM, Satchwell MF. Development of stable cell lines expressing high levels of point mutants of human opsin for biochemical and biophysical studies. Methods Enzymol. 2000;315:30-58.
27. Rumyantsev SL, Shur MS, Bilenko Y, Kosterin PV, Salzberg BM. Low frequency noise and long-term stability of noncoherent light sources. J Appl Opt. 2004;96:966-969.
28. Soukas NS, Ximenez-Fyvie LA, Hamblin MR, Socransky SS, Hasan T. Targeted antimicrobial photochemotherapy. Antimicrob Agents Chemother. 1998;42:2595-2601.
29. Moor ACE. Signaling pathways in cell death and survival after photodynamic therapy. J Photochem Photobiol B Biol. 2000;57:1-13.
30. Walter-Yohrling J, Morgenbesser S, Rouleau C, et al. Murine endothelial cell lines as models of tumor endothelial cells. Clin Canc Res. 2004;10:2179-2189.
31. Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller JW. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol. 2004;122:1002-1011.
32. 5 in ocular neovascular diseases. Proc Natl Acad Sci USA. 1996;93:9764-9769.
33. Mainster M. Wavelength selection in macular photocoagulation, tissue optics, thermal effects, and laser systems. Ophthalmology. 1986;93:952-958.
34. Stolz RA, Glazer-Hockstein C, Tolentino MJ, Maguire AM. Transmission of retinal laser wavelengths through blood. Retina. 2005; 25:498-502.
35. Allison RR, Mota HC, Bagnato VS, Sibata CH. Bio-nanotechnology and photodynamic therapy: state of the art review. Photodiagnosis Photodyn Ther. 2008;5:19-38.
36. Rolling F, Nong Z, Collen D. Adeno-associated virus-mediated gene transfer into rat carotid arteries. Gene Therapy. 1997;4:757-761.
37. Nicklin SA, Buening H, Dishart KL, de Alwis M, Girod A, et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Therapy. 2001;4:174-181.
38. Suh W, Han S-O, Ya L, Kim SW. An angiogenic, endothelial-celltargeted polymeric gene carrier. Mol Ther. 2002;6:664-672.
39. Zhu C, Zhang Y, Pardridge WM. Widespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci. 2002;43:3075-3080.
40. Ideta R, Yanagi Y, Tamaki Y, Tasaka F, Harada A, Kataoka K. Effective accumulation of polyion complex micelle to experimental choroidal neovascularization in rats. FEBS Lett. 2004;537:21-25.
41. Ogawara K-I, Rots MG, Kok RJ, et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther. 2004;15:433-443.
42. White SJ, Nicklin SA, Buning H, et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 2004;109:513-519.
43. Treynor TP, Vizcarra CL, Nedelcu D, Mayo SL. Computationally designed libraries of fluorescent proteins evaluated by preservation and diversity of function. Proc Natl Acad Sci USA. 2007;104:48-53.